A retrospective analysis of the Center for International Blood and Marrow Transplant Research (CIBMTR) database showed treatment with lisocabtagene maraleucel (liso-cel) achieved high response rates with early signs of durable benefit for real-world US patients with relapsed or refractory mantle cell lymphoma (MCL).
The analysis, led by Jennifer J. Huang, MD, PhD, of Fred Hutchinson Cancer Center of the University of Washington in Seattle, was presented at the Fourteenth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
The analysis enrolled 121 eligible patients from the CIBMTR database. The cohort was 73% male, had a median age of 71 years (range, 46-85), and 66% had one or more clinically significant comorbidities In addition, 13% of patients had a largest nodal mass over 10 cm and 31% had two or more areas of extranodal involvement. The median number of prior lines of therapy, including transplant and cellular therapy, was four (range, 2-12), and 72.5% of patients received bridging therapy.
After a median follow-up of six months (95% CI, 5.9-6.2), the objective response rate was 89% (95% CI, 82-94), and the complete response rate was 79% (95% CI, 71-86). The median duration of response, progression-free survival, and overall survival were not reached, while six-month DoR, PFS, and OS rates were 81% (95% CI, 66.5-90), 79% (95% CI, 70-86), and 92% (95% CI, 85-96), respectively.
Overall, 65% of patients had any-grade cytokine release syndrome and 36% had immune effector cell–associated neurotoxicity syndrome, with grade 3 or higher events in 2% and 14%, respectively. In addition, 24% of patients had clinically significant infections, 17% had cytopenia at day 30 post-infusion, and 7% had secondary primary malignancies, most commonly skin malignancies. In total, 14 patients died, including 10 due to disease persistence or progression. The six-month non-relapse mortality rate was 2% (95% CI, 0.3-5.5). Among 47 (39%) patients who had outpatient infusion, 60% were hospitalized post-infusion, with a median time to hospitalization of 5.5 days (range, 1-51) and a median duration of stay of five days (range, 1-32).
“Liso-cel was associated with high response rates in a broad population of patients with relapsed or refractory MCL, with early signs of durable benefit and a safety profile consistent with that reported in TRANSCEND NHL 001,” Dr. Huang and colleagues wrote.
Reference
Huang JJ, Brooks T, Romancik J, et al. Outcomes of Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Mantle Cell Lymphoma: First Real-World Data From the Center for International Blood and Marrow Transplant Research. Abstract CT-230. Presented at the 2026 Society of Hematologic Oncology Annual Meeting; September 9-12, 2026; Houston.
Watch: Elise Chong, MD, on real-world outcomes of liso-cel in MCL
Leave feedback about this